Skip to main content

Bicalutamide Disease Interactions

There is 1 disease interaction with bicalutamide.


Bicalutamide (applies to bicalutamide) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Bicalutamide is extensively metabolized by the liver and its metabolism may be altered and/or delayed in patients with moderate to severe hepatic impairment. Therapy with bicalutamide should be administered cautiously in patients with moderate to severe hepatic impairment. Additionally there have been postmarketing reports of death or hospitalization due to severe liver injury (hepatic failure) in association with bicalutamide, so extra caution is advised in patients with hepatic impairment. Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia. Clinical monitoring of hepatic function is recommended. Although hepatic abnormalities such as elevated liver transaminase levels and jaundice are usually reversible, bicalutamide therapy should be discontinued if transaminase levels exceed two times the upper normal limits.


  1. (2001) "Product Information. Casodex (bicalutamide)." Astra-Zeneca Pharmaceuticals

Bicalutamide drug interactions

There are 363 drug interactions with bicalutamide.

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.